


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:48:48Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406065" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406065</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JAMA Netw Open</journal-id><journal-id journal-id-type="iso-abbrev">JAMA Netw Open</journal-id><journal-id journal-id-type="pmc-domain-id">3211</journal-id><journal-id journal-id-type="pmc-domain">jamasd</journal-id><journal-title-group><journal-title>JAMA Network Open</journal-title></journal-title-group><issn pub-type="epub">2574-3805</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>JAMA Network</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406065</article-id><article-id pub-id-type="pmcid-ver">PMC12406065.1</article-id><article-id pub-id-type="pmcaid">12406065</article-id><article-id pub-id-type="pmcaiid">12406065</article-id><article-id pub-id-type="pmid">40892409</article-id><article-id pub-id-type="doi">10.1001/jamanetworkopen.2025.29825</article-id><article-id pub-id-type="publisher-id">zoi250843</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="category" specific-use="electronic"><subject>Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group><subj-group subj-group-type="online-only"><subject>Online Only</subject></subj-group><subj-group subj-group-type="subject-area"><subject>Health Policy</subject></subj-group></article-categories><title-group><article-title>Behavioral Economic Framing for Enrollment and Retention of Patients in Remote Blood Pressure Monitoring</article-title><subtitle>A Randomized Clinical Trial</subtitle><alt-title alt-title-type="headline">Behavioral Economic Framing for Enrollment in Remote Blood Pressure Monitoring</alt-title><alt-title alt-title-type="running-head">Behavioral Economic Framing for Enrollment in Remote Blood Pressure Monitoring</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Mehta</surname><given-names initials="SJ">Shivan J.</given-names></name><degrees>MD</degrees><degrees>MBA</degrees><degrees>MSHP</degrees><xref rid="zoi250843aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="zoi250843aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="zoi250843aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Teel</surname><given-names initials="J">Joseph</given-names></name><degrees>MD</degrees><xref rid="zoi250843aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Okorie</surname><given-names initials="E">Evelyn</given-names></name><degrees>MS</degrees><xref rid="zoi250843aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="zoi250843aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Reitz</surname><given-names initials="C">Catherine</given-names></name><degrees>MPH</degrees><xref rid="zoi250843aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="zoi250843aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Purcell</surname><given-names initials="A">Alison</given-names></name><degrees>MSN</degrees><degrees>CRNP</degrees><xref rid="zoi250843aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Snider</surname><given-names initials="CK">Christopher K.</given-names></name><degrees>MPH</degrees><xref rid="zoi250843aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Clark</surname><given-names initials="K">Kayla</given-names></name><degrees>MPH</degrees><xref rid="zoi250843aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kersting</surname><given-names initials="RC">Rebecca C.</given-names></name><degrees>MSW</degrees><xref rid="zoi250843aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Glanz</surname><given-names initials="K">Karen</given-names></name><degrees>PhD</degrees><degrees>MPH</degrees><xref rid="zoi250843aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Putt</surname><given-names initials="M">Mary</given-names></name><degrees>PhD</degrees><degrees>ScD</degrees><xref rid="zoi250843aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="zoi250843aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rareshide</surname><given-names initials="C">Charles</given-names></name><degrees>MS</degrees><xref rid="zoi250843aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Volpp</surname><given-names initials="KG">Kevin G.</given-names></name><degrees>MD</degrees><degrees>PhD</degrees><xref rid="zoi250843aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="zoi250843aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="zoi250843aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="zoi250843aff6" ref-type="aff">
<sup>6</sup>
</xref></contrib></contrib-group><aff id="zoi250843aff1"><label>1</label>Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia</aff><aff id="zoi250843aff2"><label>2</label>Center for Health Care Transformation and Innovation, University of Pennsylvania, Philadelphia</aff><aff id="zoi250843aff3"><label>3</label>Center for Health Incentives and Behavioral Economics, Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia</aff><aff id="zoi250843aff4"><label>4</label>Department of Family Medicine and Community Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia</aff><aff id="zoi250843aff5"><label>5</label>Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia</aff><aff id="zoi250843aff6"><label>6</label>Department of Health Care Management, the Wharton School, University of Pennsylvania, Philadelphia</aff><author-notes><title>Article Information</title><p><bold>Accepted for Publication:</bold> July 3, 2025.</p><p content-type="published-online"><bold>Published:</bold> September 2, 2025. doi:<uri content-type="doi">10.1001/jamanetworkopen.2025.29825</uri></p><p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link xlink:href="https://jamanetwork.com/pages/cc-by-license-permissions" ext-link-type="uri">CC-BY License</ext-link>. &#169; 2025 Mehta SJ et al. <italic toggle="yes">JAMA Network Open</italic>.</p><corresp id="zoi250843cor1"><bold>Corresponding Author:</bold> Shivan J. Mehta, MD, MBA, MSHP, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, 3600 Civic Center Blvd, 8W-206, Philadelphia, PA 19104 (<email xlink:href="shivan.mehta@pennmedicine.upenn.edu">shivan.mehta@pennmedicine.upenn.edu</email>).</corresp><p content-type="author-contributions"><bold>Author Contributions:</bold> Dr Mehta had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p><p><italic toggle="yes">Concept and design:</italic> Mehta, Okorie, Putt, Volpp.</p><p><italic toggle="yes">Acquisition, analysis, or interpretation of data:</italic> Mehta, Teel, Reitz, Purcell, Snider, Clark, Kersting, Glanz, Putt, Rareshide.</p><p><italic toggle="yes">Drafting of the manuscript:</italic> Mehta, Okorie, Reitz, Putt, Rareshide.</p><p><italic toggle="yes">Critical review of the manuscript for important intellectual content:</italic> Teel, Reitz, Purcell, Snider, Clark, Kersting, Glanz, Putt, Rareshide, Volpp.</p><p><italic toggle="yes">Statistical analysis:</italic> Putt, Rareshide.</p><p><italic toggle="yes">Obtained funding:</italic> Mehta.</p><p><italic toggle="yes">Administrative, technical, or material support:</italic> Teel, Okorie, Reitz, Purcell, Clark, Kersting, Glanz, Volpp.</p><p><italic toggle="yes">Supervision:</italic> Mehta, Teel, Reitz, Glanz.</p><p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Mehta reported receiving personal fees from Guardant Health and the American Gastroenterological Association outside the submitted work. Dr Putt reported receiving grants from the National Institutes of Health (NIH) during the conduct of the study. Dr Volpp reported receiving grants from the NIH during the conduct of the study and being a co-owner of VAL Health, a consulting company; having stock options in Thrive Global for serving on the scientific advisory board; and receiving grants from Independence Blue Cross outside the submitted work. No other disclosures were reported.</p><p content-type="funding-statement"><bold>Funding/Support:</bold> This trial was supported in part by grant number UL1TR001878 from the NCATS (Dr Volpp) and by the Institute for Translational Medicine and Therapeutics at the University of Pennsylvania. It was also supported by grant number K08CA234326 from the National Cancer Institute, NIH (Dr Mehta).</p><p><bold>Role of the Funder/Sponsor:</bold> The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p><p><bold>Disclaimer:</bold> The content is solely the responsibility of the authors and does not necessarily represent the official views of the NCATS or NIH.</p><p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-ZOI250843-1-s" ref-type="supplementary-material">Supplement 3</xref>.</p></author-notes><pub-date pub-type="epub" iso-8601-date="2025-09-02T10:00"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><volume>8</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496127</issue-id><elocation-id>e2529825</elocation-id><history><date date-type="received"><day>20</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>3</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright 2025 Mehta SJ et al. <italic toggle="yes">JAMA Network Open</italic>.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="jamanetwopen-e2529825.pdf"/><self-uri content-type="pdf-version" xlink:href="jamanetwopen-e2529825.pdf">jamanetwopen-e2529825.pdf</self-uri><self-uri content-type="silverchair" xlink:href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.29825"/><related-article related-article-type="commentary" xml:lang="en" journal-id="JAMA Netw Open" journal-id-type="nlm-ta" ext-link-type="pubmed" xlink:href="40892415"><article-title>Lessons From a Remote Blood Pressure Monitoring Trial.</article-title><volume>8</volume><issue>9</issue><date><day>2</day><month>9</month><year>2025</year></date><fpage>e2529834</fpage><lpage>e2529834</lpage><source>JAMA Netw Open</source><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2025.29834</pub-id><pub-id pub-id-type="pmid">40892415</pub-id></related-article><abstract abstract-type="teaser" specific-use="electronic"><p>This randomized clinical trial investigates whether opt-out compared with opt-in behavioral economic framing improves enrollment and engagement in remote blood pressure monitoring for adults with hypertension.</p></abstract><abstract abstract-type="key-points"><title>Key Points</title><sec id="ab-zoi250843-1"><title>Question</title><p>Can sending a blood pressure (BP) monitor to patients with hypertension and using opt-out rather than opt-in framing improve enrollment and engagement in a remote BP monitoring program?</p></sec><sec id="ab-zoi250843-2"><title>Findings</title><p>In this randomized clinical trial of 424 patients with hypertension, both opt-out and opt-in framing yielded similar rates of enrollment in a remote BP monitoring program.</p></sec><sec id="ab-zoi250843-3"><title>Meaning</title><p>The findings suggest use of opt-out behavioral economic framing may not improve patient participation in remote BP monitoring programs.</p></sec></abstract><abstract><sec id="ab-zoi250843-4"><title>Importance</title><p>Remote blood pressure (BP) monitoring for hypertension has been limited by low participation and engagement.</p></sec><sec id="ab-zoi250843-5"><title>Objective</title><p>To evaluate if an opt-out behavioral economic approach to remote BP monitoring improves enrollment and BP outcomes compared with an opt-in approach.</p></sec><sec id="ab-zoi250843-6"><title>Design, Setting, and Participants</title><p>This pragmatic, 3-arm randomized clinical trial included patients aged 18 to 75 years with hypertension who were followed up by an academic family medicine practice in Philadelphia. Eligible patients used text messaging, had at least 2 elevated BP measurements during the prior 24 months, and were prescribed hypertension medication. Patients were randomized beginning February 25, 2021, and the last patient completed the program March 22, 2022. Data were analyzed from December 2023 to January 2024.</p></sec><sec id="ab-zoi250843-7"><title>Interventions</title><p>Prior to consent, patients were randomized 2:2:1 to opt-in or opt-out recruitment for remote monitoring of BP or to usual-care control. The opt-in group received outreach to consent and enroll in remote monitoring, and those who consented received a home BP monitor; the opt-out group received a home BP monitor and similar recruitment and follow-up. For 6 months, participants in the opt-in and opt-out groups received weekly text messages requesting BP readings and received support from a social partner or clinician as needed.</p></sec><sec id="ab-zoi250843-8"><title>Main Outcomes and Measures</title><p>The primary outcome was the proportion of all participants in the intervention arms consenting to enroll in remote BP monitoring. Secondary outcomes for the intervention groups included number of BP measurements submitted and proportion of patients actively engaged. Secondary outcomes for all participants were BP measurements and the proportion with controlled BP.</p></sec><sec id="ab-zoi250843-9"><title>Results</title><p>Among 424 randomized patients (171 opt-in, 168 opt-out, and 85 control), the mean (SD) age was 52.1 (11.5) years, and 264 (62.3%) were female. A total of 58 patients (33.9%) in the opt-in and 63 (37.5%) in the opt-out arm consented to enroll in monitoring, yielding no significant difference in enrollment rate (3.6 percentage points [pp]; 90% CI, &#8722;5.0 to 12.1 pp; <italic toggle="yes">P</italic>&#8201;=&#8201;.49). There was no difference in the mean number of BP measurements submitted (unadjusted difference, &#8722;0.03 [95% CI, &#8722;0.09 to 0.03] measurements; <italic toggle="yes">P</italic>&#8201;=&#8201;.30) or proportion of actively engaged patients (absolute difference, &#8722;0.7 pp [90% CI, &#8722;15.6 to 14.3 pp]; <italic toggle="yes">P</italic>&#8201;=&#8201;.94) between intervention arms. Using BP measurements from clinic visits, 55 patients (32.2%) in the opt-in arm and 64 (38.1%) in the opt-out arm had controlled BP, compared with 18 (21.2%) in the control arm (opt-in difference vs control, 11.7 pp [95% CI, &#8722;0.2 to 23.5 pp]; <italic toggle="yes">P</italic>&#8201;=&#8201;.05; opt-out difference vs control, 18.0 pp [95% CI, 6.1-30.0 pp]; <italic toggle="yes">P</italic>&#8201;=&#8201;.003).</p></sec><sec id="ab-zoi250843-10"><title>Conclusions and Relevance</title><p>In this randomized clinical trial, the behavioral economic approach of opt-out framing vs opt-in framing did not improve enrollment and retention of patients in a remote BP monitoring program. The findings suggest additional approaches are needed to boost participation.</p></sec><sec id="ab-zoi250843-11"><title>Trial Registration</title><p>ClinicalTrials.gov Identifier: <ext-link xlink:href="https://clinicaltrials.gov/study/NCT04714398" ext-link-type="uri">NCT04714398</ext-link></p></sec></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="H1-1-ZOI250843"><title>Introduction</title><p>Hypertension is a leading cause of morbidity and mortality from cardiovascular disease.<sup><xref rid="zoi250843r1" ref-type="bibr">1</xref>,<xref rid="zoi250843r2" ref-type="bibr">2</xref>,<xref rid="zoi250843r3" ref-type="bibr">3</xref></sup> Despite effective therapies to treat hypertension, only about half of patients with hypertension have good blood pressure (BP) control.<sup><xref rid="zoi250843r4" ref-type="bibr">4</xref></sup> Remote monitoring of BP has shown effectiveness in many clinical trials, but widespread implementation has been limited by enrollment and integration into clinical practice.<sup><xref rid="zoi250843r5" ref-type="bibr">5</xref>,<xref rid="zoi250843r6" ref-type="bibr">6</xref>,<xref rid="zoi250843r7" ref-type="bibr">7</xref>,<xref rid="zoi250843r8" ref-type="bibr">8</xref>,<xref rid="zoi250843r9" ref-type="bibr">9</xref>,<xref rid="zoi250843r10" ref-type="bibr">10</xref>,<xref rid="zoi250843r11" ref-type="bibr">11</xref>,<xref rid="zoi250843r12" ref-type="bibr">12</xref>,<xref rid="zoi250843r13" ref-type="bibr">13</xref></sup> For remote monitoring to be effective, patients need to participate, and the information needs to be acted on in a way that is timely but does not overburden primary care clinicians.</p><p>There is an opportunity to increase participation in remote BP monitoring by incorporating insights from the field of behavioral economics, which acknowledges that humans have systematic biases in thinking that can be harnessed to improve healthy behavior.<sup><xref rid="zoi250843r14" ref-type="bibr">14</xref>,<xref rid="zoi250843r15" ref-type="bibr">15</xref>,<xref rid="zoi250843r16" ref-type="bibr">16</xref></sup> Shifting from opt-in to opt-out framing has dramatically increased participation in cancer screening and vaccinations.<sup><xref rid="zoi250843r17" ref-type="bibr">17</xref>,<xref rid="zoi250843r18" ref-type="bibr">18</xref>,<xref rid="zoi250843r19" ref-type="bibr">19</xref></sup> The endowment effect indicates that people place more value on something they possess as opposed to something they could obtain.<sup><xref rid="zoi250843r20" ref-type="bibr">20</xref></sup> In addition, humans are influenced by others through social support, which can include encouragement from friends or family members.<sup><xref rid="zoi250843r21" ref-type="bibr">21</xref>,<xref rid="zoi250843r22" ref-type="bibr">22</xref></sup> In the case of remote BP monitoring, sending a BP cuff with an invitation and including opt-out framing and social support could increase enrollment, engagement, and effectiveness of the program. In this trial, we evaluated whether opt-out framing after providing remote BP monitoring cuffs to patients with hypertension preenrollment increased both enrollment in the program and clinical effectiveness of a remote BP monitoring intervention.</p></sec><sec id="H1-2-ZOI250843"><title>Methods</title><sec id="H2-1-ZOI250843"><title>Study Design</title><p>This was a 3-arm randomized clinical trial applying behavioral approaches to encourage patients with hypertension to manage their BP using a remote monitoring program. Eligible patients were randomized in a 2:2:1 ratio into 3 arms: (1) opt-in recruitment, (2) opt-out recruitment (including a BP cuff provided preenrollment), or (3) control. The study was approved by the institutional review board (IRB) at the University of Pennsylvania. A waiver of informed consent for the enrollment phase of the study was obtained because this phase of the study posed minimal risk to patients and could not have been carried out practicably without the waiver.<sup><xref rid="zoi250843r23" ref-type="bibr">23</xref></sup> Participation in remote monitoring required patients to provide oral consent via telephone. The IRB waived informed consent for patients in the control arm because there was low risk and obtaining consent would have precluded evaluation of usual care. The study followed the Consolidated Standards of Reporting Trials (<ext-link xlink:href="http://www.equator-network.org/reporting-guidelines/consort/" ext-link-type="uri">CONSORT</ext-link>) reporting guideline. The protocol and statistical plan appear in <xref rid="note-ZOI250843-1-s" ref-type="supplementary-material">Supplement 1</xref>.</p></sec><sec id="H2-2-ZOI250843"><title>Study Population</title><p>The study included patients followed up by a large family medicine practice at an urban academic health system in Philadelphia. We included patients between the ages of 18 and 75 years who had text messaging capability, a diagnosis of hypertension, at least 2 visits to the practice within the past 2 years, and at least 2 BP measurements that exceeded Eighth Joint National Committee hypertension guidelines (including at the most recent visit at the time of medical record review) and who were prescribed at least 1 medication for hypertension.<sup><xref rid="zoi250843r24" ref-type="bibr">24</xref></sup> We excluded patients with a body mass index (BMI, calculated as weight in kilograms divided by height in meters squared) greater than or equal to 50, since they would likely require a different BP cuff; patients with a history of metastatic (stage 4) cancer, end-stage kidney disease, heart failure, and/or dementia, as their participation in the trial may not be clinically appropriate; and patients designated as non&#8211;English speaking and requiring a translator, as the intervention was text-based.</p><p>Race and ethnicity data, included in the analysis because there are known disparities in engagement and outcomes for hypertension,<sup><xref rid="zoi250843r1" ref-type="bibr">1</xref>,<xref rid="zoi250843r4" ref-type="bibr">4</xref></sup> were based on self-reported data in the EHR. Race categories were Asian, Black, White, and other (included Pacific Islander, multiracial, or other race) or unknown (included patients with missing data or who self-identified their race as &#8220;unknown&#8221;). Ethnicity categories were Hispanic or Latino and not Hispanic or Latino.</p></sec><sec id="H2-3-ZOI250843"><title>Recruitment and Randomization</title><p>Patients were identified through automated data extraction from the electronic health record (EHR) in February 2021, with additional medical record review performed by research staff to confirm eligibility. In variable blocks of 5 and 10 using a computer-generated algorithm, eligible patients were randomized in a 2:2:1 ratio to opt-in, opt-out, and control.</p><p>Patients in the opt-in recruitment arm received an invitation letter and up to 3 recruitment telephone calls to obtain verbal consent for remote monitoring. After consent, the research coordinators (E.O., K.C.) mailed a BP cuff and initiated the remote monitoring program. Patients were also asked (but not required) to provide names of up to 3 friends or family members to serve as a support partner, who then provided verbal agreement to participate but not formal consent.</p><p>Patients assigned to the opt-out recruitment arm received an electronic BP cuff (OMRON 3 Series [OMRON Healthcare Inc], or Welch Allyn 1700 Series [Welch Allyn Inc] if BMI &gt;40) with a letter describing the program and opt-out framing regarding their participation. Patients in this arm received similar recruitment and follow-up to the opt-in arm.</p><p>Patients in the control arm were not contacted by study staff and received usual care, which involved management of hypertension by the PCP, typically through routine office visits. Eligible patients were randomized beginning February 25, 2021, and enrolled in remote monitoring between March 4, 2021, and September 22, 2021. Patients were enrolled on a rolling basis, and the last enrolled patient completed the program March 22, 2022. Investigators were blinded to arm allocation, but research staff were not, as they needed to administer the intervention. The trial was pragmatic in its integration into clinical operations and the EHR, and BP outcomes measured from routine visits.</p></sec><sec id="H2-4-ZOI250843"><title>Interventions</title><p>For 6 months, all patients in the remote monitoring groups received text message prompts 3 times per week asking to input BP and once per week asking how often they had taken their BP medication. They also received facts about BP and lifestyle changes and feedback regarding their BP control.</p><p>Escalations occurred in the following scenarios: (1) chronic escalations (3 out of 10 BP readings above guidelines),<sup><xref rid="zoi250843r25" ref-type="bibr">25</xref></sup> (2) severely high escalations (any single systolic BP [SBP] measurement &#8805;180 mm Hg and/or diastolic BP [DBP] measurement &#8805;110 mm Hg), or (3) severely low escalations (any single SBP measurement &lt;90 mm Hg and/or DBP measurement &lt;50 mm Hg). Escalations were noted to the patient via text message and routed to either the nursing pool (chronic escalations) or directly to the nurse practitioner (A.P.) (severely high or low escalations). All patient-submitted BP measurements were visible in the EHR BP flow sheet.</p><p>A support partner was added to the program after a patient&#8217;s first chronic escalation to help provide encouragement. The partner received weekly updates about the patient&#8217;s medication adherence and BP monitoring and was notified if the patient&#8217;s BPs were routinely elevated above a certain threshold. The partner was encouraged to talk to the patient about BP control and had the opportunity to opt out of a weekly support message sent to the patient on the partner&#8217;s behalf.</p><p>If a patient&#8217;s BP measurements triggered a second escalation, a nurse or the nurse practitioner could contact them via the study text-messaging platform to obtain additional information, provide additional guidelines for BP management, or set up a telephone consultation. If BP measurements triggered a third escalation, the nurse practitioner was encouraged to consider changing the dosing of the patient&#8217;s existing medications, change their medications, or prescribe additional medications to help manage their BP. Patients nonresponsive to texting prompts were contacted by the study team with reengagement attempts after 7, 14, 21, and 35 consecutive missed prompts. All text-messaging content appears in the protocol in <xref rid="note-ZOI250843-1-s" ref-type="supplementary-material">Supplement 1</xref>.</p></sec><sec id="H2-5-ZOI250843"><title>Study Outcomes</title><p>The primary outcome was the proportion of patients consenting to receive remote monitoring out of the total number randomized. For the intervention arms, secondary outcomes included the proportion of the requested BP measurements submitted by each patient and the proportion of patients actively engaged with the program (defined as submitting at least 50% of the requested BP measurements), based on a prior trial.<sup><xref rid="zoi250843r26" ref-type="bibr">26</xref></sup> For participants in all arms, we compared the mean number of BP measurements recorded in the EHR between 6 and 12 months after randomization and the final SBP level in the control vs intervention arms.</p></sec><sec id="H2-6-ZOI250843"><title>Statistical Analysis</title><p>An intention-to-treat analysis was used for the primary outcome and the secondary outcomes of controlled BP and actual BP measurements collected from the EHR. For the intervention arms, secondary outcomes (engagement with the program, BP control) were based on participants who consented postrandomization. The primary analysis compared the proportion of patients participating in each study arm using a <italic toggle="yes">Z</italic> test with 90% CIs, as this was a pilot study (type I error rate was .10). The study will inform enrollment rates that can be used to guide study design and enrollment goals for future trials. For a sample size of 170 per opt-in and opt-out group, if the observed difference in rates was 10% and the rate for the opt-in group was 30%, the 90% CI would have a half-width of 9.0%, with boundaries of 1.0% and 19.0%. Additionally, using a 2-sided type I error rate of .10, this study design had 80% power to detect an absolute difference of 12.9 percentage points (pp) between the opt-out and opt-in arms. Except for the primary outcome, we used 95% CIs as per convention.</p><p>For the primary end point, we also conducted a logistic regression model with adjustment for demographic and clinical characteristics (age, BMI, sex, race, insurance type, and diabetes and kidney disease status). We also compared the mean rates of participation in BP measurements using a logistic regression model adjusted for the number of BP measurements requested as well as demographic and clinical variables. Similarly, we estimated the odds of engagement (defined as submitting at least 50% of the requested BP measurements over the duration of the program), with adjustment for baseline variables.</p><p>We estimated the total proportion of patients with controlled BP in the intervention and control arms, using all randomized participants as the denominator to follow intention-to-treat principles. Using a linear model, we determined whether mean BP differed by arm after adjustment for baseline BP and used the model to provide estimates of both final BP and changes in BP from baseline. To address missing data, we conducted multiple imputation of the BP data using a monotone predicted mean matching method in SAS Studio, version 3.82 (SAS Institute Inc), fit to each of the 20 imputations and combined using Rubin method. The variables for imputation included study arm, age, BMI, sex, race, insurance status, diabetes, chronic kidney disease, and eligibility BP. Data were analyzed from December 2023 to January 2024 using SAS Studio, version 3.82. Two-sided <italic toggle="yes">P</italic>&#8201;&lt;&#8201;.05 was considered significant.</p></sec></sec><sec id="H1-3-ZOI250843"><title>Results</title><sec id="H2-7-ZOI250843"><title>Patient Characteristics</title><p>A total of 620 patients in the medical record reviews had confirmed eligibility, and 425 were randomized (171 to opt-in, 168 to opt-out, and 85 to control); 1 patient was erroneously randomized and removed from the study before outreach (<xref rid="zoi250843f1" ref-type="fig">Figure</xref>). The mean (SD) patient age was 52.1 (11.5) years (range, 23-75 years); 264 (62.3%) were female and 160 (37.7%) were male. A total of 135 (31.8%) were insured by Medicaid and 203 (47.9%) had private insurance or were self-paying. Eleven patients (2.6%) were Asian, 365 (86.1%) were Black, 33 (7.8%) were White, and 15 (3.5%) were of other or unknown race; 13 (3.1%) identified as Hispanic or Latino and 407 (96.0%) as not Hispanic or Latino, and 4 (0.9%) had unknown ethnicity (<xref rid="zoi250843t1" ref-type="table">Table 1</xref>). A total of 139 of the 424 patients randomized (32.7%) did not have a clinic visit during the study and were therefore missing data on BP.</p><fig position="float" id="zoi250843f1" fig-type="figure" orientation="portrait"><label>Figure. </label><caption><title>Consolidated Standards of Reporting Trials Flow Diagram</title><p>BMI indicates body mass index (calculated as weight in kilograms divided by height in meters squared); BP, blood pressure; CHF, congestive heart failure; EHR, electronic health record; ITT, intention to treat; NA, not applicable; WNL, within normal limits.</p><p><sup>a</sup>Some patients were excluded for more than 1 reason.</p><p><sup>b</sup>The primary outcome was the number of patients consenting to remote monitoring (RM) out of the number randomized and was not applicable to patients in the control arm.</p><p><sup>c</sup>Engagement analyses included the number of patients actively engaged with the RM program (submitting at least 50% of requested BP measurements) out of the total number consenting to RM and were not applicable to patients in the control arm.</p><p><sup>d</sup>Patients included in the BP analysis had at least 1 ambulatory BP measurement in the EHR between 6 and 12 months from the date of randomization.</p></caption><graphic position="float" orientation="portrait" xlink:href="jamanetwopen-e2529825-g001.jpg"/></fig><table-wrap position="float" id="zoi250843t1" orientation="portrait"><label>Table 1. </label><caption><title>Participant Characteristics</title></caption><table frame="hsides" rules="groups"><col width="31.28%" span="1"/><col width="16.61%" span="1"/><col width="17.75%" span="1"/><col width="16.61%" span="1"/><col width="17.75%" span="1"/><thead><tr><th rowspan="3" valign="top" align="left" scope="rowgroup" colspan="1">Characteristic</th><th colspan="4" valign="top" align="left" scope="colgroup" rowspan="1">Participants<xref rid="zoi250843t1n1" ref-type="table-fn"><sup>a</sup></xref></th></tr><tr><th colspan="3" valign="top" align="left" scope="colgroup" rowspan="1">Study arm</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Overall (N&#8201;=&#8201;424)</th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Opt-in (n&#8201;=&#8201;171)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Opt-out (n&#8201;=&#8201;168)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Control (n&#8201;=&#8201;85)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Age, mean (SD), y</td><td valign="top" align="left" rowspan="1" colspan="1">52.2 (12.1)</td><td valign="top" align="left" rowspan="1" colspan="1">52.4 (11.5)</td><td valign="top" align="left" rowspan="1" colspan="1">51.5 (10.2)</td><td valign="top" align="left" rowspan="1" colspan="1">52.1 (11.5)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Sex</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Female</td><td valign="top" align="left" rowspan="1" colspan="1">108 (63.2)</td><td valign="top" align="left" rowspan="1" colspan="1">102 (60.7)</td><td valign="top" align="left" rowspan="1" colspan="1">54 (63.5)</td><td valign="top" align="left" rowspan="1" colspan="1">264 (62.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Male</td><td valign="top" align="left" rowspan="1" colspan="1">63 (36.8)</td><td valign="top" align="left" rowspan="1" colspan="1">66 (39.3)</td><td valign="top" align="left" rowspan="1" colspan="1">31 (36.5)</td><td valign="top" align="left" rowspan="1" colspan="1">160 (37.7)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Race</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Asian</td><td valign="top" align="left" rowspan="1" colspan="1">7 (4.1)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (0.6)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (3.5)</td><td valign="top" align="left" rowspan="1" colspan="1">11 (2.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Black</td><td valign="top" align="left" rowspan="1" colspan="1">143 (83.6)</td><td valign="top" align="left" rowspan="1" colspan="1">146 (86.9)</td><td valign="top" align="left" rowspan="1" colspan="1">76 (89.4)</td><td valign="top" align="left" rowspan="1" colspan="1">365 (86.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> White</td><td valign="top" align="left" rowspan="1" colspan="1">16 (9.4)</td><td valign="top" align="left" rowspan="1" colspan="1">13 (7.7)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (4.7)</td><td valign="top" align="left" rowspan="1" colspan="1">33 (7.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Other or unknown<xref rid="zoi250843t1n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">5 (2.9)</td><td valign="top" align="left" rowspan="1" colspan="1">8 (4.8)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (2.6)</td><td valign="top" align="left" rowspan="1" colspan="1">15 (3.5)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Ethnicity</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hispanic or Latino</td><td valign="top" align="left" rowspan="1" colspan="1">7 (4.1)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (1.2)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (4.7)</td><td valign="top" align="left" rowspan="1" colspan="1">13 (3.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Not Hispanic or Latino</td><td valign="top" align="left" rowspan="1" colspan="1">163 (95.3)</td><td valign="top" align="left" rowspan="1" colspan="1">163 (97.0)</td><td valign="top" align="left" rowspan="1" colspan="1">81 (95.3)</td><td valign="top" align="left" rowspan="1" colspan="1">407 (96.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Unknown</td><td valign="top" align="left" rowspan="1" colspan="1">1 (0.6)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (1.8)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">4 (0.9)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Insurance</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Private or self-pay</td><td valign="top" align="left" rowspan="1" colspan="1">94 (55.0)</td><td valign="top" align="left" rowspan="1" colspan="1">70 (41.7)</td><td valign="top" align="left" rowspan="1" colspan="1">39 (45.9)</td><td valign="top" align="left" rowspan="1" colspan="1">203 (47.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Medicare</td><td valign="top" align="left" rowspan="1" colspan="1">36 (21.1)</td><td valign="top" align="left" rowspan="1" colspan="1">39 (23.2)</td><td valign="top" align="left" rowspan="1" colspan="1">11 (12.9)</td><td valign="top" align="left" rowspan="1" colspan="1">86 (20.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Medicaid</td><td valign="top" align="left" rowspan="1" colspan="1">41 (24.0)</td><td valign="top" align="left" rowspan="1" colspan="1">59 (35.1)</td><td valign="top" align="left" rowspan="1" colspan="1">35 (41.2)</td><td valign="top" align="left" rowspan="1" colspan="1">135 (31.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">BMI, mean (SD)</td><td valign="top" align="left" rowspan="1" colspan="1">33.5 (6.1)</td><td valign="top" align="left" rowspan="1" colspan="1">32.9 (6.4)</td><td valign="top" align="left" rowspan="1" colspan="1">33.8 (6.6)</td><td valign="top" align="left" rowspan="1" colspan="1">33.3 (6.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Diabetes</td><td valign="top" align="left" rowspan="1" colspan="1">68 (39.8)</td><td valign="top" align="left" rowspan="1" colspan="1">66 (39.3)</td><td valign="top" align="left" rowspan="1" colspan="1">28 (32.9)</td><td valign="top" align="left" rowspan="1" colspan="1">162 (38.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Kidney disease</td><td valign="top" align="left" rowspan="1" colspan="1">14 (8.2)</td><td valign="top" align="left" rowspan="1" colspan="1">23 (13.7)</td><td valign="top" align="left" rowspan="1" colspan="1">8 (9.4)</td><td valign="top" align="left" rowspan="1" colspan="1">45 (10.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Eligibility systolic BP, mean (SD)</td><td valign="top" align="left" rowspan="1" colspan="1">151.2 (14.1)</td><td valign="top" align="left" rowspan="1" colspan="1">152.3 (14.1)</td><td valign="top" align="left" rowspan="1" colspan="1">149.8 (12.2)</td><td valign="top" align="left" rowspan="1" colspan="1">151.4 (13.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Eligibility diastolic BP, mean (SD)</td><td valign="top" align="left" rowspan="1" colspan="1">89.3 (11.7)</td><td valign="top" align="left" rowspan="1" colspan="1">88.0 (14)</td><td valign="top" align="left" rowspan="1" colspan="1">90.1 (11.2)</td><td valign="top" align="left" rowspan="1" colspan="1">89.0 (12.6)</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); BP, blood pressure.</p><fn id="zoi250843t1n1"><label>
<sup>a</sup>
</label><p>Data are presented as number (percentage) of participants unless otherwise indicated.</p></fn><fn id="zoi250843t1n2"><label>
<sup>b</sup>
</label><p>Includes patients who self-identified as Pacific Islander, other race, or multiracial in the electronic health record. Unknown includes those missing data and those who self-identified as unknown.</p></fn></table-wrap-foot></table-wrap></sec><sec id="H2-8-ZOI250843"><title>Recruitment Outcomes</title><p>Among patients randomized, 58 (33.9%) in the opt-in arm and 63 (37.5%) in the opt-out arm consented to participate (<xref rid="zoi250843f1" ref-type="fig">Figure</xref>). The participant characteristics of those who consented within each intervention arm were generally similar, with the notable exception of insurance (eTable 1 in <xref rid="note-ZOI250843-1-s" ref-type="supplementary-material">Supplement 2</xref>). We found no statistically significant difference in the rate of consent between arms (3.6 pp; 90% CI, &#8722;5.0 to 12.1 pp; <italic toggle="yes">P</italic>&#8201;=&#8201;.49) (<xref rid="zoi250843t2" ref-type="table">Table 2</xref>). Neither the unadjusted odds of consent (odds ratio [OR], 1.17; 95% CI, 0.75-1.82; <italic toggle="yes">P</italic>&#8201;=&#8201;.49) nor the odds of consent adjusted for age, BMI, sex, race, insurance type, diabetes, and kidney disease status (adjusted OR [AOR], 1.16; 95% CI, 0.73-1.84; <italic toggle="yes">P</italic>&#8201;=&#8201;.54) were significantly different from the control group. Out of the 121 patients that enrolled, 58 (47.9%) identified a support partner, and 9 of those identified (15.5%) enrolled as a partner.</p><table-wrap position="float" id="zoi250843t2" orientation="portrait"><label>Table 2. </label><caption><title>Rates and Odds of Consent for Intervention Arms</title></caption><table frame="hsides" rules="groups"><col width="17.49%" span="1"/><col width="14.41%" span="1"/><col width="13.38%" span="1"/><col width="18.53%" span="1"/><col width="9.26%" span="1"/><col width="18.72%" span="1"/><col width="8.21%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="rowgroup" colspan="1"/><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Participants, No. (%)</th><th colspan="4" valign="top" align="left" scope="colgroup" rowspan="1">Effect</th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Opt-in (n&#8201;=&#8201;171)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Opt-out (n&#8201;=&#8201;168)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Rate difference (90% CI), pp<xref rid="zoi250843t2n1" ref-type="table-fn"><sup>a</sup></xref></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">OR (90% CI)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Consented (unadjusted)</td><td valign="top" align="left" rowspan="1" colspan="1">58 (33.9)</td><td valign="top" align="left" rowspan="1" colspan="1">63 (37.5)</td><td valign="top" align="left" rowspan="1" colspan="1">3.6 (&#8722;5.0 to 12.1)</td><td valign="top" align="left" rowspan="1" colspan="1">.49</td><td valign="top" align="left" rowspan="1" colspan="1">1.17 (0.75-1.82)</td><td valign="top" align="left" rowspan="1" colspan="1">.49</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Consented (adjusted)<xref rid="zoi250843t2n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">1.16 (0.73-1.84)</td><td valign="top" align="left" rowspan="1" colspan="1">.54</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: NA, not applicable; OR, odds ratio; pp, percentage points.</p><fn id="zoi250843t2n1"><label>
<sup>a</sup>
</label><p>Difference in opt-out vs opt-in rates.</p></fn><fn id="zoi250843t2n2"><label>
<sup>b</sup>
</label><p>Adjusted for age, body mass index, sex, race, insurance type, and diabetes and kidney disease status.</p></fn></table-wrap-foot></table-wrap></sec><sec id="H2-9-ZOI250843"><title>Engagement Outcomes</title><p>The opt-in arm submitted a mean (SD) of 40.5 (28.1) BP measurements and the opt-out arm submitted 39.3 (27.2). The mean number of BP measurements submitted was not significantly different between arms in unadjusted (difference, &#8722;0.03 [95% CI, &#8722;0.09 to 0.03] measurements; <italic toggle="yes">P</italic>&#8201;=&#8201;.30) or adjusted (difference, &#8722;0.04 [95% CI, &#8722;0.10 to 0.02] measurements; <italic toggle="yes">P</italic>&#8201;=&#8201;.16) analyses (eTable 2 in <xref rid="note-ZOI250843-1-s" ref-type="supplementary-material">Supplement 2</xref>). The proportion of actively engaged patients (submitting at least 50% of requested BP measurements) was nearly identical between intervention arms: 30 of the 58 patients (51.7%) in the opt-in arm were considered actively engaged vs 33 of 63 (52.4%) in the opt-out arm, an absolute difference of &#8722;0.7 pp (90% CI, &#8722;15.6 to 14.3 pp; <italic toggle="yes">P</italic>&#8201;=&#8201;.94) (eTable 3 in <xref rid="note-ZOI250843-1-s" ref-type="supplementary-material">Supplement 2</xref>).</p></sec><sec id="H2-10-ZOI250843"><title>BP Outcomes</title><p>There were similar proportions of patients with clinic BP readings in the opt-in (112 [65.5%]), opt-out (117 [69.6%]), and control (56 [65.9%]) arms. However, using intention-to-treat analyses, 55 patients (32.2%) in the opt-in and 64 (38.1%) in the opt-out study arms showed BP control, compared with 18 (21.2%) in the control arm. Compared with the control arm, patients in the opt-out but not the opt-in arm had significantly higher rates of showing BP control (opt-in difference, 11.7 pp [95% CI, &#8722;0.2 to 23.5 pp]; <italic toggle="yes">P</italic>&#8201;=&#8201;.05; opt-out difference, 18.0 pp [95% CI, 6.1-30.0 pp]; <italic toggle="yes">P</italic>&#8201;=&#8201;.003) (<xref rid="zoi250843t3" ref-type="table">Table 3</xref>). An analysis using multiple imputation to address missing data yielded similar findings, as did a random-effects model to account for individuals with multiple BP measurements.</p><table-wrap position="float" id="zoi250843t3" orientation="portrait"><label>Table 3. </label><caption><title>Differences in Rates of Controlled Blood Pressure by Study Arm<xref rid="zoi250843t3n1" ref-type="table-fn"><sup>a</sup></xref></title></caption><table frame="hsides" rules="groups"><col width="22.88%" span="1"/><col width="28.84%" span="1"/><col width="9.72%" span="1"/><col width="28.84%" span="1"/><col width="9.72%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="rowgroup" colspan="1">Model</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Opt-in arm</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Opt-out arm</th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Difference (95% CI), pp</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Difference (95% CI), pp</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Control arm as reference</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Unadjusted</td><td valign="top" align="left" rowspan="1" colspan="1">11.7 (&#8722;0.2 to 23.5)</td><td valign="top" align="left" rowspan="1" colspan="1">.05</td><td valign="top" align="left" rowspan="1" colspan="1">18.0 (6.1 to 30.0)</td><td valign="top" align="left" rowspan="1" colspan="1">.003</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Adjusted<xref rid="zoi250843t3n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">12.9 (0.1 to 24.8)</td><td valign="top" align="left" rowspan="1" colspan="1">.03</td><td valign="top" align="left" rowspan="1" colspan="1">19.9 (7.9 to 31.9)</td><td valign="top" align="left" rowspan="1" colspan="1">.001</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Opt-in arm as reference</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Unadjusted</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">6.3 (&#8722;3.3 to 16.0)</td><td valign="top" align="left" rowspan="1" colspan="1">.20</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Adjusted<xref rid="zoi250843t3n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">7.0 (&#8722;2.8-16.8)</td><td valign="top" align="left" rowspan="1" colspan="1">.16</td></tr></tbody></table><table-wrap-foot><p>Abbreviation: NA, not applicable.</p><fn id="zoi250843t3n1"><label>
<sup>a</sup>
</label><p>Controlled blood pressure (BP) was defined as systolic BP less than 140 mm Hg and diastolic BP less than 90 mm Hg.</p></fn><fn id="zoi250843t3n2"><label>
<sup>b</sup>
</label><p>Adjusted for age, body mass index, sex, race, insurance type, and diabetes and kidney disease status.</p></fn></table-wrap-foot></table-wrap><p>The mean (SD) eligibility SBP was 151.2 mm Hg (14.1 mm Hg) in the opt-in, 152.3 mm Hg (14.1 mm Hg) in the opt-out, and 149.8 mm Hg (12.2 mm Hg) in the control arm. Compared with the final SBP level in the control arm (mean [SD], 143.9 [15.2] mm Hg), final SBP levels were lower in the opt-in (mean [SD], 139.4 [13.5] mm Hg; difference vs control: &#8722;4.77 mm Hg [95% CI, &#8722;9.19 to &#8722;0.35 mm Hg]; <italic toggle="yes">P</italic>&#8201;=&#8201;.03) and opt-out (mean [SD], 138.5 [14.7] mm Hg; difference vs control: &#8722;6.26 mm Hg [95% CI, &#8722;10.67 to &#8722;1.84 mm Hg]; <italic toggle="yes">P</italic>&#8201;=&#8201;.006) arms (<xref rid="zoi250843t4" ref-type="table">Table 4</xref>). Similar results were found when adjusting for demographic and clinical characteristics and in analyses with random effects or multiple imputation. With the same adjustments, final DBP levels in the opt-in (difference, &#8722;1.77 mm Hg; 95% CI, &#8722;4.60 to 1.06 mm Hg; <italic toggle="yes">P</italic>&#8201;=&#8201;.22) and opt-out (difference, &#8722;2.09 mm Hg; 95% CI, &#8722;4.92 to 0.74 mm Hg; <italic toggle="yes">P</italic>&#8201;=&#8201;.15) arms were not significantly different from the control group (eTable 4 in <xref rid="note-ZOI250843-1-s" ref-type="supplementary-material">Supplement 2</xref>). Patient-submitted BP readings are shown in eTable 5 in <xref rid="note-ZOI250843-1-s" ref-type="supplementary-material">Supplement 2</xref>, and patient reported medication adherence is shown in eTable 6 in <xref rid="note-ZOI250843-1-s" ref-type="supplementary-material">Supplement 2</xref>.</p><table-wrap position="float" id="zoi250843t4" orientation="portrait"><label>Table 4. </label><caption><title>Differences in Mean Systolic Blood Pressure by Study Arm</title></caption><table frame="hsides" rules="groups"><col width="12.58%" span="1"/><col width="36.17%" span="1"/><col width="7.54%" span="1"/><col width="36.17%" span="1"/><col width="7.54%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="rowgroup" colspan="1">Model</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Opt-in arm</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Opt-out arm</th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Difference, mean (95% CI), mm Hg</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Difference, mean (95% CI), mm Hg</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Control arm as reference</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Unadjusted</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;4.77 (&#8722;9.19 to &#8722;0.35)</td><td valign="top" align="left" rowspan="1" colspan="1">.03</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;6.26 (&#8722;10.67 to &#8722;1.84)</td><td valign="top" align="left" rowspan="1" colspan="1">.006</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Adjusted<xref rid="zoi250843t4n1" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;4.64 (&#8722;9.12 to &#8722;0.16)</td><td valign="top" align="left" rowspan="1" colspan="1">.04</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;6.51 (&#8722;10.99 to &#8722;2.02)</td><td valign="top" align="left" rowspan="1" colspan="1">.005</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Imputed<xref rid="zoi250843t4n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;4.7 (&#8722;9.3 to 0.0)</td><td valign="top" align="left" rowspan="1" colspan="1">.048</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;5.9 (&#8722;10.4 to &#8722;1.3)</td><td valign="top" align="left" rowspan="1" colspan="1">.01</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Opt-in arm as reference</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Unadjusted</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;1.48 (&#8722;5.07 to 2.11)</td><td valign="top" align="left" rowspan="1" colspan="1">.42</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Adjusted<xref rid="zoi250843t4n1" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;1.87 (&#8722;5.58 to 1.84)</td><td valign="top" align="left" rowspan="1" colspan="1">.32</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Imputed<xref rid="zoi250843t4n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;1.2 (&#8722;4.6 to 2.2)</td><td valign="top" align="left" rowspan="1" colspan="1">.49</td></tr></tbody></table><table-wrap-foot><p>Abbreviation: NA, not applicable.</p><fn id="zoi250843t4n1"><label>
<sup>a</sup>
</label><p>Adjusted for age, body mass index, sex, race, insurance type, and diabetes and kidney disease status.</p></fn><fn id="zoi250843t4n2"><label>
<sup>b</sup>
</label><p>Imputed with 20 imputations using a monotone predicted mean matching method.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="H1-4-ZOI250843"><title>Discussion</title><p>In this pragmatic randomized clinical trial, participation among patients receiving the opt-out framing, by mailing the BP monitor before enrollment, was not substantially increased compared with those receiving opt-in framing. However, both intervention groups, who were offered remote BP monitoring, showed improved BP control compared with the control group. Of note, the intention-to-treat population included both those who enrolled in the BP monitoring and those who did not, enabling evaluation of the effect of the intervention when offered in routine clinical practice.</p><p>Prior studies have shown that sending screening kits, a laboratory order, and electronic pill bottles with outreach can increase participation by framing participation as opt-out and leveraging reciprocity.<sup><xref rid="zoi250843r18" ref-type="bibr">18</xref>,<xref rid="zoi250843r27" ref-type="bibr">27</xref>,<xref rid="zoi250843r28" ref-type="bibr">28</xref>,<xref rid="zoi250843r29" ref-type="bibr">29</xref>,<xref rid="zoi250843r30" ref-type="bibr">30</xref></sup> There are several possible reasons why this trial did not show improved enrollment among the group that received the BP monitor ahead of time. First, this was not a true opt-out program, as the patients still needed to answer the telephone and consent to monitoring before they were enrolled. Second, the messaging about consent was similar between arms, so patients may not have thought the intervention was part of routine care (as it would be when implemented in clinical practice). Additionally, the prior outreach studies did not include a telephone call or consent component. While our study was designed to detect fairly large effects, as it had 80% power to detect about a 13-pp increase in enrollment, the estimated difference between arms of 3.6 pp (90% CI, &#8722;5.0 to 12.1 pp) is consistent with a null improvement from the opt-out intervention. In addition, limited enrollment rates might reflect our strategy of reaching out directly to patients not undergoing BP control, without referral from their primary care practitioner (PCP).</p><p>There has been mixed evidence of effectiveness in studies of remote monitoring for hypertension, with heterogeneity in the design of interventions and integration into clinical practice.<sup><xref rid="zoi250843r5" ref-type="bibr">5</xref>,<xref rid="zoi250843r6" ref-type="bibr">6</xref>,<xref rid="zoi250843r7" ref-type="bibr">7</xref>,<xref rid="zoi250843r8" ref-type="bibr">8</xref>,<xref rid="zoi250843r10" ref-type="bibr">10</xref>,<xref rid="zoi250843r31" ref-type="bibr">31</xref></sup> In our own health system, 2 trials of text message engagement were conducted that required research consent to participate but did not show improved BP control. The first trial provided text messaging reminders for medication adherence, but there was no BP monitoring or connection to a clinician.<sup><xref rid="zoi250843r32" ref-type="bibr">32</xref></sup> The second trial provided remote BP monitoring, but results outside the healthy range were first sent directly to the PCP, who lacked capacity to manage the alerts outside of office visits; halfway through the study, based on feedback from the clinicians, the results were sent to a dedicated nurse practitioner.<sup><xref rid="zoi250843r26" ref-type="bibr">26</xref></sup> The improvement seen in BP control among patients in the current study could be attributed to several factors. First, the dedicated escalation pathway approached care in a stepped manner, so that initially, a nurse talked to the patients about adherence, and then a dedicated nurse practitioner could prescribe medications. Second, this study included additional behavioral interventions, such as social support and feedback. Third, this study did not require a separate BP visit for the final outcome measure. In prior studies, the control group was consented and required to participate in an end-of-study visit for BP measurement, which in itself may have acted as an intervention.<sup><xref rid="zoi250843r25" ref-type="bibr">25</xref>,<xref rid="zoi250843r26" ref-type="bibr">26</xref></sup> This study&#8217;s findings also suggest that even those patients who were contacted but not consented to participate in remote monitoring had slightly better BP control than patients in the control arm, as the outreach (and the BP monitor in the opt-out arm) may have provided a nudge for patients to take their medications and control their BP. Fourth, there was a longer follow-up time frame of 6 months, compared with 4 months in prior studies.<sup><xref rid="zoi250843r26" ref-type="bibr">26</xref>,<xref rid="zoi250843r32" ref-type="bibr">32</xref></sup></p><sec id="H2-11-ZOI250843"><title>Strengths and Limitations</title><p>The main strength of this study was its pragmatic design that was integrated into routine practice, with a technology platform embedded in the EHR and outcomes that were obtained from routine office visits. Therefore, the results likely simulate what would happen if the intervention were implemented in clinical practice. Intention-to-treat analyses were possible for the primary outcome and for the clinic-based outcomes (BP control and BP measurements), although we acknowledge substantial missingness in these clinic-based outcomes in that 32.7% of patients did not have a clinic visit during the study. We included all patients randomized as the denominator for patients with controlled BP, which likely underestimated actual control. To address the missing data, we carried out a multiple imputation. The study also included a large proportion of Black patients (86.1%), who typically have worse outcomes for hypertension, potentially helping to mitigate disparities.</p><p>The main limitation of the study was that the BP readings from routine visits may have been subject to selection factors or variation in measurement. This was due to the pragmatic nature of the study, which relied on routine clinical office visits for BP outcomes rather than dedicated research measurement; thus, we did not have BP data for about one-third of the patients.<sup><xref rid="zoi250843r26" ref-type="bibr">26</xref></sup> However, the proportion of patients with clinic BP readings was similar across arms, and we found similar results with multiple imputation. Additionally, the first tier of escalation for patients was to receive social support, but this proved unavailable to many patients who may have benefited from it. The study also relied on dedicated clinical staff for the intervention, which may be hard to generalize in other health systems. As this was a pragmatic study, we also did not have access to prescription fill and robust medication adherence data.</p></sec></sec><sec id="H1-5-ZOI250843"><title>Conclusions</title><p>This randomized clinical trial found that opt-out framing, by sending participants a BP monitor, was not more effective at increasing participation in remote BP management than opt-in framing, consisting of a recruitment letter and telephone calls to obtain consent before sending a BP monitor. However, the remote monitoring intervention overall improved BP control compared with usual care in the control arm. The findings suggest that future interventions are needed to make it easier for patients to participate in remote BP monitoring and to understand which components are most important for a successful program when implemented.</p></sec></body><back><ref-list id="REF-ZOI250843"><title>References</title><ref id="zoi250843r1"><label>1</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Muntner</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Miles</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Jaeger</surname><given-names>BC</given-names></string-name>, <etal/></person-group>. <article-title>Blood pressure control among US adults, 2009 to 2012 through 2017 to 2020</article-title>. <source>Hypertension</source>. <year>2022</year>;<volume>79</volume>(<issue>9</issue>):<fpage>1971</fpage>-<lpage>1980</lpage>. doi:<pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.122.19222</pub-id><pub-id pub-id-type="pmid">35616029</pub-id><pub-id pub-id-type="pmcid">PMC9370255</pub-id></mixed-citation></ref><ref id="zoi250843r2"><label>2</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Forouzanfar</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Roth</surname><given-names>GA</given-names></string-name>, <etal/></person-group>. <article-title>Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015</article-title>. <source>JAMA</source>. <year>2017</year>;<volume>317</volume>(<issue>2</issue>):<fpage>165</fpage>-<lpage>182</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2016.19043</pub-id><pub-id pub-id-type="pmid">28097354</pub-id></mixed-citation></ref><ref id="zoi250843r3"><label>3</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Murray</surname><given-names>CJL</given-names></string-name>, <string-name name-style="western"><surname>Lopez</surname><given-names>AD</given-names></string-name></person-group>. <article-title>Measuring the global burden of disease</article-title>. <source>N Engl J Med</source>. <year>2013</year>;<volume>369</volume>(<issue>5</issue>):<fpage>448</fpage>-<lpage>457</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMra1201534</pub-id><pub-id pub-id-type="pmid">23902484</pub-id></mixed-citation></ref><ref id="zoi250843r4"><label>4</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Chobufo</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Gayam</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Soluny</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Prevalence and control rates of hypertension in the USA: 2017-2018</article-title>. <source>Int J Cardiol Hypertens</source>. <year>2020</year>;<volume>6</volume>:<elocation-id>100044</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.ijchy.2020.100044</pub-id><pub-id pub-id-type="pmid">33447770</pub-id><pub-id pub-id-type="pmcid">PMC7803011</pub-id></mixed-citation></ref><ref id="zoi250843r5"><label>5</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Bosworth</surname><given-names>HB</given-names></string-name>, <string-name name-style="western"><surname>Powers</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Olsen</surname><given-names>MK</given-names></string-name>, <etal/></person-group>. <article-title>Home blood pressure management and improved blood pressure control: results from a randomized controlled trial</article-title>. <source>Arch Intern Med</source>. <year>2011</year>;<volume>171</volume>(<issue>13</issue>):<fpage>1173</fpage>-<lpage>1180</lpage>. doi:<pub-id pub-id-type="doi">10.1001/archinternmed.2011.276</pub-id><pub-id pub-id-type="pmid">21747013</pub-id></mixed-citation></ref><ref id="zoi250843r6"><label>6</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Margolis</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Asche</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Bergdall</surname><given-names>AR</given-names></string-name>, <etal/></person-group>. <article-title>Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial</article-title>. <source>JAMA</source>. <year>2013</year>;<volume>310</volume>(<issue>1</issue>):<fpage>46</fpage>-<lpage>56</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2013.6549</pub-id><pub-id pub-id-type="pmid">23821088</pub-id><pub-id pub-id-type="pmcid">PMC4311883</pub-id></mixed-citation></ref><ref id="zoi250843r7"><label>7</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Omboni</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Guarda</surname><given-names>A</given-names></string-name></person-group>. <article-title>Impact of home blood pressure telemonitoring and blood pressure control: a meta-analysis of randomized controlled studies</article-title>. <source>Am J Hypertens</source>. <year>2011</year>;<volume>24</volume>(<issue>9</issue>):<fpage>989</fpage>-<lpage>998</lpage>. doi:<pub-id pub-id-type="doi">10.1038/ajh.2011.100</pub-id><pub-id pub-id-type="pmid">21654858</pub-id></mixed-citation></ref><ref id="zoi250843r8"><label>8</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Choi</surname><given-names>WS</given-names></string-name>, <string-name name-style="western"><surname>Choi</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Oh</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Shin</surname><given-names>IS</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>JS</given-names></string-name></person-group>. <article-title>Effects of remote monitoring of blood pressure in management of urban hypertensive patients: a systematic review and meta-analysis</article-title>. <source>Telemed J E Health</source>. <year>2020</year>;<volume>26</volume>(<issue>6</issue>):<fpage>744</fpage>-<lpage>759</lpage>. doi:<pub-id pub-id-type="doi">10.1089/tmj.2019.0028</pub-id><pub-id pub-id-type="pmid">31532328</pub-id></mixed-citation></ref><ref id="zoi250843r9"><label>9</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Uhlig</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Patel</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Ip</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kitsios</surname><given-names>GD</given-names></string-name>, <string-name name-style="western"><surname>Balk</surname><given-names>EM</given-names></string-name></person-group>. <article-title>Self-measured blood pressure monitoring in the management of hypertension: a systematic review and meta-analysis</article-title>. <source>Ann Intern Med</source>. <year>2013</year>;<volume>159</volume>(<issue>3</issue>):<fpage>185</fpage>-<lpage>194</lpage>. doi:<pub-id pub-id-type="doi">10.7326/0003-4819-159-3-201308060-00008</pub-id><pub-id pub-id-type="pmid">23922064</pub-id></mixed-citation></ref><ref id="zoi250843r10"><label>10</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Green</surname><given-names>BB</given-names></string-name>, <string-name name-style="western"><surname>Cook</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Ralston</surname><given-names>JD</given-names></string-name>, <etal/></person-group>. <article-title>Effectiveness of home blood pressure monitoring, Web communication, and pharmacist care on hypertension control: a randomized controlled trial</article-title>. <source>JAMA</source>. <year>2008</year>;<volume>299</volume>(<issue>24</issue>):<fpage>2857</fpage>-<lpage>2867</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.299.24.2857</pub-id><pub-id pub-id-type="pmid">18577730</pub-id><pub-id pub-id-type="pmcid">PMC2715866</pub-id></mixed-citation></ref><ref id="zoi250843r11"><label>11</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Margolis</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Asche</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Dehmer</surname><given-names>SP</given-names></string-name>, <etal/></person-group>. <article-title>Long-term outcomes of the effects of home blood pressure telemonitoring and pharmacist management on blood pressure among adults with uncontrolled hypertension: follow-up of a cluster randomized clinical trial</article-title>. <source>JAMA Netw Open</source>. <year>2018</year>;<volume>1</volume>(<issue>5</issue>):<elocation-id>e181617</elocation-id>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2018.1617</pub-id><pub-id pub-id-type="pmid">30646139</pub-id><pub-id pub-id-type="pmcid">PMC6324502</pub-id></mixed-citation></ref><ref id="zoi250843r12"><label>12</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Cappuccio</surname><given-names>FP</given-names></string-name>, <string-name name-style="western"><surname>Kerry</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Forbes</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Donald</surname><given-names>A</given-names></string-name></person-group>. <article-title>Blood pressure control by home monitoring: meta-analysis of randomised trials</article-title>. <source>BMJ</source>. <year>2004</year>;<volume>329</volume>(<issue>7458</issue>):<fpage>145</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.38121.684410.AE</pub-id><pub-id pub-id-type="pmid">15194600</pub-id><pub-id pub-id-type="pmcid">PMC478224</pub-id></mixed-citation></ref><ref id="zoi250843r13"><label>13</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Kronish</surname><given-names>IM</given-names></string-name>, <string-name name-style="western"><surname>Kent</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Moise</surname><given-names>N</given-names></string-name>, <etal/></person-group>. <article-title>Barriers to conducting ambulatory and home blood pressure monitoring during hypertension screening in the United States</article-title>. <source>J Am Soc Hypertens</source>. <year>2017</year>;<volume>11</volume>(<issue>9</issue>):<fpage>573</fpage>-<lpage>580</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jash.2017.06.012</pub-id><pub-id pub-id-type="pmid">28734798</pub-id><pub-id pub-id-type="pmcid">PMC5595651</pub-id></mixed-citation></ref><ref id="zoi250843r14"><label>14</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Kahneman</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Tversky</surname><given-names>A</given-names></string-name></person-group>. <article-title>Prospect theory: an analysis of decision under risk</article-title>. <source>Econometrica</source>. <year>1979</year>;<volume>47</volume>(<issue>2</issue>):<fpage>263</fpage>-<lpage>291</lpage>. doi:<pub-id pub-id-type="doi">10.2307/1914185</pub-id></mixed-citation></ref><ref id="zoi250843r15"><label>15</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Tversky</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kahneman</surname><given-names>D</given-names></string-name></person-group>. <article-title>Judgment under uncertainty: heuristics and biases</article-title>. <source>Science</source>. <year>1974</year>;<volume>185</volume>(<issue>4157</issue>):<fpage>1124</fpage>-<lpage>1131</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.185.4157.1124</pub-id><pub-id pub-id-type="pmid">17835457</pub-id></mixed-citation></ref><ref id="zoi250843r16"><label>16</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Tversky</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kahneman</surname><given-names>D</given-names></string-name></person-group>. <article-title>The framing of decisions and the psychology of choice</article-title>. <source>Science</source>. <year>1981</year>;<volume>211</volume>(<issue>4481</issue>):<fpage>453</fpage>-<lpage>458</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.7455683</pub-id><pub-id pub-id-type="pmid">7455683</pub-id></mixed-citation></ref><ref id="zoi250843r17"><label>17</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Chapman</surname><given-names>GB</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Colby</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yoon</surname><given-names>H</given-names></string-name></person-group>. <article-title>Opting in vs opting out of influenza vaccination</article-title>. <source>JAMA</source>. <year>2010</year>;<volume>304</volume>(<issue>1</issue>):<fpage>43</fpage>-<lpage>44</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2010.892</pub-id><pub-id pub-id-type="pmid">20606147</pub-id></mixed-citation></ref><ref id="zoi250843r18"><label>18</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Mehta</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Khan</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Guerra</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>A randomized controlled trial of opt-in versus opt-out colorectal cancer screening outreach</article-title>. <source>Am J Gastroenterol</source>. <year>2018</year>;<volume>113</volume>(<issue>12</issue>):<fpage>1848</fpage>-<lpage>1854</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41395-018-0151-3</pub-id><pub-id pub-id-type="pmid">29925915</pub-id><pub-id pub-id-type="pmcid">PMC6768589</pub-id></mixed-citation></ref><ref id="zoi250843r19"><label>19</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Waddell</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Mehta</surname><given-names>SJ</given-names></string-name></person-group>. <article-title>Designing effective and appropriate opt-out approaches for patient outreach</article-title>. <source>JAMA Intern Med</source>. <year>2023</year>;<volume>183</volume>(<issue>11</issue>):<fpage>1194</fpage>-<lpage>1195</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamainternmed.2023.4628</pub-id><pub-id pub-id-type="pmid">37695578</pub-id><pub-id pub-id-type="pmcid">PMC10810178</pub-id></mixed-citation></ref><ref id="zoi250843r20"><label>20</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Kahneman</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Knetsch</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Thaler</surname><given-names>RH</given-names></string-name></person-group>. <article-title>Anomalies: the endowment effect, loss aversion, and status quo bias</article-title>. <source>J Econ Perspect</source>. <year>1991</year>;<volume>5</volume>(<issue>1</issue>):<fpage>193</fpage>-<lpage>206</lpage>. doi:<pub-id pub-id-type="doi">10.1257/jep.5.1.193</pub-id></mixed-citation></ref><ref id="zoi250843r21"><label>21</label><mixed-citation publication-type="book"><person-group><string-name name-style="western"><surname>Cialdini</surname><given-names>RB</given-names></string-name>, <string-name name-style="western"><surname>Trost</surname><given-names>MR</given-names></string-name></person-group>. <part-title>Social influence: social norms, conformity and compliance</part-title>. In: <person-group><string-name name-style="western"><surname>Gilbert</surname><given-names>DT</given-names></string-name>, <string-name name-style="western"><surname>Fiske</surname><given-names>ST</given-names></string-name>, <string-name name-style="western"><surname>Lindzey</surname><given-names>G</given-names></string-name></person-group>, eds. <source>The Handbook of Social Psychology</source>. <edition>4th ed</edition>. <publisher-name>McGraw-Hill</publisher-name>; <year>1998</year>:<fpage>151</fpage>-<lpage>192</lpage>.</mixed-citation></ref><ref id="zoi250843r22"><label>22</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Asch</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Rosin</surname><given-names>R</given-names></string-name></person-group>. <article-title>Engineering social incentives for health</article-title>. <source>N Engl J Med</source>. <year>2016</year>;<volume>375</volume>(<issue>26</issue>):<fpage>2511</fpage>-<lpage>2513</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMp1603978</pub-id><pub-id pub-id-type="pmid">28029924</pub-id></mixed-citation></ref><ref id="zoi250843r23"><label>23</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Asch</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Ziolek</surname><given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Mehta</surname><given-names>SJ</given-names></string-name></person-group>. <article-title>Misdirections in informed consent&#8212;impediments to health care innovation</article-title>. <source>N Engl J Med</source>. <year>2017</year>;<volume>377</volume>(<issue>15</issue>):<fpage>1412</fpage>-<lpage>1414</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMp1707991</pub-id><pub-id pub-id-type="pmid">29020586</pub-id></mixed-citation></ref><ref id="zoi250843r24"><label>24</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>James</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Oparil</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Carter</surname><given-names>BL</given-names></string-name>, <etal/></person-group>. <article-title>2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)</article-title>. <source>JAMA</source>. <year>2014</year>;<volume>311</volume>(<issue>5</issue>):<fpage>507</fpage>-<lpage>520</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2013.284427</pub-id><pub-id pub-id-type="pmid">24352797</pub-id></mixed-citation></ref><ref id="zoi250843r25"><label>25</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Sharman</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Blizzard</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Kosmala</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Nelson</surname><given-names>MR</given-names></string-name></person-group>. <article-title>Pragmatic method using blood pressure diaries to assess blood pressure control</article-title>. <source>Ann Fam Med</source>. <year>2016</year>;<volume>14</volume>(<issue>1</issue>):<fpage>63</fpage>-<lpage>69</lpage>. doi:<pub-id pub-id-type="doi">10.1370/afm.1883</pub-id><pub-id pub-id-type="pmid">26755785</pub-id><pub-id pub-id-type="pmcid">PMC4709157</pub-id></mixed-citation></ref><ref id="zoi250843r26"><label>26</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Mehta</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Volpp</surname><given-names>KG</given-names></string-name>, <string-name name-style="western"><surname>Troxel</surname><given-names>AB</given-names></string-name>, <etal/></person-group>. <article-title>Remote blood pressure monitoring with social support for patients with hypertension: a randomized clinical trial</article-title>. <source>JAMA Netw Open</source>. <year>2024</year>;<volume>7</volume>(<issue>6</issue>):<elocation-id>e2413515</elocation-id>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2024.13515</pub-id><pub-id pub-id-type="pmid">38829618</pub-id><pub-id pub-id-type="pmcid">PMC11148689</pub-id></mixed-citation></ref><ref id="zoi250843r27"><label>27</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Mehta</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Day</surname><given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Norris</surname><given-names>AH</given-names></string-name>, <etal/></person-group>. <article-title>Behavioral interventions to improve population health outreach for hepatitis C screening: randomized clinical trial</article-title>. <source>BMJ</source>. <year>2021</year>;<volume>373</volume>(<issue>1022</issue>):<fpage>n1022</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.n1022</pub-id><pub-id pub-id-type="pmid">34006604</pub-id><pub-id pub-id-type="pmcid">PMC8129827</pub-id></mixed-citation></ref><ref id="zoi250843r28"><label>28</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Mehta</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Rhodes</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Linn</surname><given-names>KA</given-names></string-name>, <etal/></person-group>. <article-title>Behavioral interventions to improve breast cancer screening outreach: two randomized clinical trials</article-title>. <source>JAMA Intern Med</source>. <year>2024</year>;<volume>184</volume>(<issue>7</issue>):<fpage>761</fpage>-<lpage>768</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamainternmed.2024.0495</pub-id><pub-id pub-id-type="pmid">38709509</pub-id><pub-id pub-id-type="pmcid">PMC11074930</pub-id></mixed-citation></ref><ref id="zoi250843r29"><label>29</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Mehta</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Troxel</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Marcus</surname><given-names>N</given-names></string-name>, <etal/></person-group>. <article-title>Participation rates with opt-out enrollment in a remote monitoring intervention for patients with myocardial infarction</article-title>. <source>JAMA Cardiol</source>. <year>2016</year>;<volume>1</volume>(<issue>7</issue>):<fpage>847</fpage>-<lpage>848</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamacardio.2016.2374</pub-id><pub-id pub-id-type="pmid">27603755</pub-id><pub-id pub-id-type="pmcid">PMC6140334</pub-id></mixed-citation></ref><ref id="zoi250843r30"><label>30</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Kahneman</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Knetsch</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Thaler</surname><given-names>RH</given-names></string-name></person-group>. <article-title>Experimental tests of the endowment effect and the Coase theorem</article-title>. <source>J Polit Econ</source>. <year>1990</year>;<volume>98</volume>(<issue>6</issue>):<fpage>1325</fpage>-<lpage>1348</lpage>. doi:<pub-id pub-id-type="doi">10.1086/261737</pub-id></mixed-citation></ref><ref id="zoi250843r31"><label>31</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Noah</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Keller</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Mosadeghi</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Impact of remote patient monitoring on clinical outcomes: an updated meta-analysis of randomized controlled trials</article-title>. <source>NPJ Digit Med</source>. <year>2018</year>;<volume>1</volume>(<issue>1</issue>):<fpage>20172</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41746-017-0002-4</pub-id><pub-id pub-id-type="pmid">31304346</pub-id><pub-id pub-id-type="pmcid">PMC6550143</pub-id></mixed-citation></ref><ref id="zoi250843r32"><label>32</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Mehta</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Volpp</surname><given-names>KG</given-names></string-name>, <string-name name-style="western"><surname>Troxel</surname><given-names>AB</given-names></string-name>, <etal/></person-group>. <article-title>Electronic pill bottles or bidirectional text messaging to improve hypertension medication adherence (Way 2 Text): a randomized clinical trial</article-title>. <source>J Gen Intern Med</source>. <year>2019</year>;<volume>34</volume>(<issue>11</issue>):<fpage>2397</fpage>-<lpage>2404</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11606-019-05241-x</pub-id><pub-id pub-id-type="pmid">31396815</pub-id><pub-id pub-id-type="pmcid">PMC6848522</pub-id></mixed-citation></ref></ref-list><notes notes-type="supplementary-material" id="note-ZOI250843-1"><supplementary-material id="note-ZOI250843-1-s" position="float" content-type="local-data" orientation="portrait"><label>Supplement 1.</label><caption><p>
Trial Protocol
</p></caption><media xlink:href="jamanetwopen-e2529825-s001.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material position="float" content-type="local-data" orientation="portrait"><label>Supplement 2.</label><caption><p><bold>eTable 1.</bold> Characteristics of Consented Participants in Intervention Arms</p><p><bold>eTable 2.</bold> Average Number of Blood Pressure (BP) Readings Submitted by Arm</p><p><bold>eTable 3.</bold> Rate of Engagement in BP Monitoring by Arm (at Least 50% of BPs Submitted)</p><p><bold>eTable 4.</bold> Mean Diastolic Blood Pressure and Differences by Arm</p><p><bold>eTable 5.</bold> Patient Submitted Blood Pressures by Arm</p><p><bold>eTable 6.</bold> Patient Reported Medication Adherence by Arm</p></caption><media xlink:href="jamanetwopen-e2529825-s002.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material position="float" content-type="local-data" orientation="portrait"><label>Supplement 3.</label><caption><p>
Data Sharing Statement
</p></caption><media xlink:href="jamanetwopen-e2529825-s003.pdf" position="float" orientation="portrait"/></supplementary-material></notes></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>